Ann Pediatr Endocrinol Metab.  2020 Mar;25(1):24-30. 10.6065/apem.2020.25.1.24.

Relationship between final adult height and birth weight after gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty

• Cho AY
• Ko SY
• Lee JH
• Kim EY

• KMID: 2501033
• DOI: http://doi.org/10.6065/apem.2020.25.1.24

Abstract

Purpose
The clinical significance of birth weight relative to gestational age in girls with central precocious puberty is unclear. This study sought to compare clinical parameters such as final adult height (FAH) and menarche onset after treatment with gonadotropin-releasing hormone agonist (GnRHa) on birth weight in girls with central precocious puberty treated.
Methods
This retrospective study reviewed data of 69 girls with precocious puberty who had reached their FAH in a long-term trial of GnRHa treatment between January 2007 and December 2017. The subjects were divided into small for gestational age (SGA) (n=19) and appropriate for gestational age (AGA) (n=50) groups.
Results
When starting GnRHa treatment, bone age was 10.9±0.9 and 10.3±0.8 years in the SGA and AGA groups, respectively (P<0.05). The predicted adult height (PAH) (established according to the Bayley-Pinneau average table) and advanced PAH (established according to the Bayley-Pinneau advanced table) were 151.5±4.8 cm and 155.8±4.9 cm in the SGA group, respectively, and 153.4±5.3 cm and 159.0±6.0 cm in the AGA group. After treatment, no significant difference in bone age was found between the groups. The time to menarche after treatment was 12.5±7.6 and 21.1±12.3 months in the SGA and AGA groups, respectively (P<0.05). FAH in the SGA and AGA groups was 161.0±4.7 cm and 161.6±5.0 cm, respectively, without a significant difference.
Conclusion
SGA girls with precocious puberty have increased bone age and earlier menarche relative to AGA girls. However, no difference in FAH after treatment was found between these groups.

Keyword

Precocious puberty; Gonadotropin-releasing hormone; Birth weight

Figure

• 

  Fig. 1. (A) Period of menarch after GnRHa treatment in SGA group. (B) Period of menarch after GnRHa treatment in AGA group. GnRHa, gonadotropin-releasing hormone agonist; SGA, small for gestational age; AGA, appropriate for gestational age.

• 

  Fig. 2. Changes of PAH, PAHa, and FAH during GnRHa treatment. TH, target height; GnRHa, gonadotropin-releasing hormone agonist; PAH, predicted adult height-according to Baley-Pinneau's average table; PAHa, Predicted adult height-according to Baley-Pinneau’s advanced table; FAH, final adult height; NS, not significant. * P<0.05 compared with FAH.

Reference

References

1. Carel JC, Léger J. Clinical practice. Precocious puberty. N Engl J Med. 2008; 358:2366–77.

2. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropinreleasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr. 1998; 157:363–7.

3. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000; 13 Suppl 1:723–37.

4. Jung MK, Song KC, Kwon AR, Chae HW, Kim DH, Kim HS. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone. Ann Pediatr Endocrinol Metab. 2014; 19:214–9.

5. Ying Y, Tang J, Chen W, Cai Z, Niu WT. GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls. Oncotarget. 2017; 8:109061–7.

6. Kim SY. Growth and sex differentiation of children born small for gestational age. Korean J Pediatr. 2009; 52:142–51.

7. Albertsson-Wikland K. Growth hormone treatment in short children. Acta Paediatr Scand Suppl. 1986; 325:64–70.

8. Hokken-Koelega AC, De Ridder MA, Lemmen RJ, Den Hartog H, De Muinck Keizer-Schrama SM, Drop SL. Children born small for gestational age: do they catch up? Pediatr Res. 1995; 38:267–71.

9. Ibáñez L, Jiménez R, de Zegher F. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics. 2006; 117:117–21.

10. Persson I, Ahlsson F, Ewald U, Tuvemo T, Qingyuan M, von Rosen D, et al. Influence of perinatal factors on the onset of puberty in boys and girls: implications for interpretation of link with risk of long term diseases. Am J Epidemiol. 1999; 150:747–55.

11. Hernández MI, Martínez A, Capurro T, Peña V, Trejo L, Avila A, et al. Comparison of clinical, ultrasonographic, and biochemical differences at the beginning of puberty in healthy girls born either small for gestational age or appropriate for gestational age: preliminary results. J Clin Endocrinol Metab. 2006; 91:3377–81.

12. Veening MA, van Weissenbruch MM, Roord JJ, de Delemarre-van Waal HA. Pubertal development in children born small for gestational age. J Pediatr Endocrinol Metab. 2004; 17:1497–505.

13. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford (CA): Stanford University Press;1971.

14. Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr. 1952; 40:423–41.

15. Lazar L, Pollak U, Kalter-Leibovici O, Pertzelan A, Phillip M. Pubertal course of persistently short children born small for gestational age (SGA) compared with idiopathic short children born appropriate for gestational age (AGA). Eur J Endocrinol. 2003; 149:425–32.

16. Ibáñez L, Ferrer A, Marcos MV, Hierro FR, de Zegher F. Early puberty: rapid progression and reduced final height in girls with low birth weight. Pediatrics. 2000; 106:E72.

17. Hernández MI, Mericq V. Pubertal development in girls born small for gestational age. J Pediatr Endocrinol Metab. 2008; 21:201–8.

18. Hofman PL, Cutfield WS, Robinson EM, Bergman RN, Menon RK, Sperling MA, et al. Insulin resistance in short children with intrauterine growth retardation. J Clin Endocrinol Metab. 1997; 82:402–6.

19. Cara JF, Rosenfield RL. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 1988; 123:733–9.

20. Lee HS, Yoon JS, Park KJ, Hwang JS. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. PLoS One. 2018; 13:e0201906.

21. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab. 2005; 90:1371–6.